Drug intelligence / Profile preview

RC148 + RC88

Development stage: Unknown
Lead developer: RemeGen
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

RC148 + RC88 is a combination therapy being investigated for the treatment of advanced solid tumors. RC148 is a bispecific antibody targeting PD-1/VEGF, while RC88 is a mesothelin-targeting antibody-drug conjugate (ADC) with monomethyl auristatin E (MMAE) as the payload. This combination is being explored as part of RemeGen's strategy to maximize therapeutic potential through combining ADCs with bispecific antibodies.

Targets

MesothelinVEGFA (Vascular endothelial growth factor A)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on RC148 + RC88.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RC148 + RC88.

Explore the full profile